Metallacycle-mediated coupling in stereoselective synthesis
立体选择性合成中金属环介导的偶联
基本信息
- 批准号:10317087
- 负责人:
- 金额:$ 57.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlkaloidsAreaBenzoquinonesBiologicalBiologyCardenolidesChemicalsChemistryComplexCouplingCytotoxic agentDevelopmentEstrogen Receptor betaFoundationsGoalsInvestigationLaboratoriesLigandsMediatingMedicineMethodsMultiple MyelomaNatural ProductsOrganic ChemistryOrganic SynthesisPharmaceutical ChemistryPlayProcessPropertyReactionResearchRoleSchemeScienceSkeletonSteroidsTP53 geneTechnologyTerpenesTextilesTherapeuticVertebral columnVisionbasechemical synthesisclinically relevantcycloadditiondesignforginginhibitorinnovationinterestlupeolnon-opioid analgesicnovelparalogous geneprogramssmall moleculestemtargeted agenttool
项目摘要
1. Project Summary/Abstract:
Research Overview – Research is focused on organic synthesis, with particular interest in developing
synthesis strategies and modes of reactivity within organic chemistry that facilitate the construction of
complex molecules with potentially valuable medicinal and/or biological properties. We have developed
over thirty stereoselective C–C bond-forming reactions based on areas of reactivity that include
metallacycle-mediated cross-coupling, [3+2] cycloaddition, vinylcyclopropane rearrangement, and radical
cascade chemistry. While some of these have been developed within a program aimed at achieving a
foundation of reactivity suitable to realize a wide range of unique “convergent” C–C bond forming
processes, others have emerged within programs in the broad area of natural product synthesis. These
combined activities, that aim to advance the fundamental backbone of organic chemistry through innovation
within the field of stereoselective synthesis, are routinely embraced as enabling technology to fuel
exploration in medicinally relevant science. For example, we have discovered: (1) a non-opioid analgesic
from efforts targeting the alkaloid conolidine, (2) unique paralog selective Hsp90 inhibitors stemming from
explorations into the synthesis of benzoquinone ansamycins, (3) selectively cytotoxic agents targeting
multiple myeloma from activities associated with the synthesis of lehualide B, (4) the first non-peptidic
selective ligand to the DBD of p53 with a natural product-inspired oligomerization, and (5) the most potent
and selective agonist of the estrogen receptor beta (ERβ) from recent investigations targeting terpenoids.
Overall Vision of the Program – This seamless integration of reaction development, natural product
synthesis, and efforts to employ our technology as an enabling tool for the discovery of novel compositions
of matter with unique biological properties defines the basic fabric of science that has been, and will
continue to be, the focus of science in the Micalizio laboratory for decades to come.
Goals for the Next Five Years – Efforts will focus on natural product total synthesis, new reaction
development, and establishing a conceptually unified asymmetric entry to tetracyclic and pentacyclic
terpenoids. These activities include target-oriented synthesis campaigns around ryanodol, corialactone D,
azadiradione (limonoid), samandarin (steroidal alkaloid), oleandrin (cardenolide), euphol (euphane), and
lupeol (pentacyclic triterpenoid). These activites have, at their core, the ambition to establish and
demonstrate novel synthesis designs and reaction methods in the context of a wide range of complex
natural products. An emerging interest is to establish a general “common” asymmetric and step economical
synthetic strategy capable of forging diverse classes of terpenoid skeletons. Contributions in this area will
clearly guide our natural product pursuits, but also play a central role in efforts to design/discover natural
product-inspired agents targeting a range of medicinally relevant biology.
1.项目摘要/摘要:
研究概述-研究的重点是有机合成,特别是开发
有机化学中促进构筑的合成策略和反应模式
具有潜在有价值的药用和/或生物特性的复杂分子。我们已经开发出
30多个基于反应性区域的立体选择性C-C键形成反应,包括
金属环介导的交叉偶联、[3+2]环加成、乙烯基环丙烷重排和自由基
级联化学。虽然其中一些是在一个计划内开发的,旨在实现
适合实现多种独特的“收敛”碳-碳键形成的反应性基础
在天然产物合成这一广泛领域的项目中,也出现了一些新的过程。这些
综合活动,旨在通过创新推动有机化学的基本支柱
在立体选择性合成领域,通常被认为是使技术成为燃料
在与医学相关的科学方面的探索。例如,我们发现:(1)一种非阿片类止痛药
从针对刀豆碱的生物碱的努力中,(2)独特的准对数选择性Hsp90抑制剂源于
苯醌阿霉素类药物的合成探索(3)选择性靶向细胞毒药物
多发性骨髓瘤与合成活动相关的乐华内酯B,(4)第一个非肽类
具有天然产物启发的寡聚作用的P53的DBD的选择性配体,以及(5)最有效的
以及最近针对萜类化合物的雌激素受体β(ERβ)的选择性激动剂。
该计划的总体愿景-反应开发、天然产品的无缝集成
合成,以及努力利用我们的技术作为发现新组合物的使能工具
具有独特生物性质的物质定义了科学的基本结构,这种结构已经并将
继续是Micalizio实验室未来几十年的科学重点。
未来五年的目标-努力将重点放在天然产物全合成,新反应
发展,并建立了概念上统一的四环和五环不对称进入
萜类化合物。这些活动包括以目标为导向的围绕兰诺醇,科里拉内酯D,
氮杂二酮(柠檬苦素)、萨芒达林(类固醇生物碱)、齐墩果苷(卡地奈德)、安息香酚(安非他明)和
羽扇豆醇(五环三萜)。这些活动的核心是建立和建立
在广泛的复杂背景下展示新的合成设计和反应方法
天然产品。一个新出现的兴趣是建立一种普遍的“共同”不对称和步步经济
能够锻造不同类别的萜类骨架的合成策略。在这一领域的贡献将
清楚地指导我们对自然产品的追求,但也在设计/发现自然产品的努力中发挥核心作用
以产品为灵感的药物,目标是一系列与医学相关的生物学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GLENN C MICALIZIO其他文献
GLENN C MICALIZIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GLENN C MICALIZIO', 18)}}的其他基金
Metallacycle-mediated coupling in stereoselective synthesis
立体选择性合成中金属环介导的偶联
- 批准号:
10540398 - 财政年份:2020
- 资助金额:
$ 57.4万 - 项目类别:
Class II Directed Carbometalation Processes for Heterocycle Synthesis
用于杂环合成的 II 类定向碳金属化工艺
- 批准号:
7891992 - 财政年份:2009
- 资助金额:
$ 57.4万 - 项目类别:
Class II Directed Carbometalation Processes for Heterocycle Synthesis
用于杂环合成的 II 类定向碳金属化工艺
- 批准号:
8037034 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Stereoselective Synthesis via Metallacycle-Mediated Bond Construction
通过金属环介导的键构建进行立体选择性合成
- 批准号:
8535780 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Stereoselective Synthesis via Metallacycle-Mediated Bond Construction
通过金属环介导的键构建进行立体选择性合成
- 批准号:
8664650 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Class II Directed Carbometalation Processes for Heterocycle Synthesis
用于杂环合成的 II 类定向碳金属化工艺
- 批准号:
7382520 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Class II Directed Carbometalation Processes for Heterocycle Synthesis
用于杂环合成的 II 类定向碳金属化工艺
- 批准号:
7572838 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Stereoselective Synthesis via Metallacycle-Mediated Bond Construction
通过金属环介导的键构建进行立体选择性合成
- 批准号:
8652468 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Class II Directed Carbometalation Processes for Heterocycle Synthesis
用于杂环合成的 II 类定向碳金属化工艺
- 批准号:
7771722 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
Stereoselective Synthesis via Metallacycle-Mediated Bond Construction
通过金属环介导的键构建进行立体选择性合成
- 批准号:
8372060 - 财政年份:2007
- 资助金额:
$ 57.4万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 57.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 57.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 57.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)